Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Phase 4

Completed

Conditions: Lymphoma, Low-Grade
Lymphoma, Non-Hodgkin

First Posted Date: 2005-09-15

Last Posted Date: 2023-08-23

Lead Sponsor: Biogen

Target Recruit Count: 12

Registration Number: NCT00168727

Locations: 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸
Northwest Oncology and Hematology, Elk Grove Village, Illinois, United States
🇺🇸
Medical Specialists of Fairfield, Fairfield, Connecticut, United States

and more 5 locations

AVONEX® Combination Trial - "ACT"

Phase 4

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2005-05-30

Last Posted Date: 2008-05-09

Lead Sponsor: Biogen

Target Recruit Count: 350

Registration Number: NCT00112034

Locations: 🇺🇸
MS Academic Coordinating Center, Cleveland, Ohio, United States

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Phase 1

Completed

Conditions: Colorectal Carcinoma
Metastases

First Posted Date: 2005-04-12

Last Posted Date: 2009-07-14

Lead Sponsor: Biogen

Target Recruit Count: 44

Registration Number: NCT00107861

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States

Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Tumors

First Posted Date: 2005-03-09

Last Posted Date: 2013-04-26

Lead Sponsor: Biogen

Target Recruit Count: 13

Registration Number: NCT00105170

Locations: 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2005-02-11

Last Posted Date: 2015-10-02

Lead Sponsor: Biogen

Target Recruit Count: 31

Registration Number: NCT00103558

Locations: 🇺🇸
Research Site, Houston, Texas, United States

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Phase 1

Terminated

Conditions: Metastases
Colorectal Cancer

First Posted Date: 2005-01-20

Last Posted Date: 2010-08-27

Lead Sponsor: Biogen

Target Recruit Count: 30

Registration Number: NCT00102024

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Phase 2

Completed

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy

First Posted Date: 2004-12-16

Last Posted Date: 2010-03-05

Lead Sponsor: Biogen

Target Recruit Count: 67

Registration Number: NCT00099489

Locations: 🇺🇸
Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States
🇬🇧
Guy's Hospital/Dept. of Neuroimmunology, London, United Kingdom
🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

and more 17 locations

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Natalizumab
Drug: Placebo

First Posted Date: 2004-12-01

Last Posted Date: 2009-06-18

Lead Sponsor: Biogen

Target Recruit Count: 110

Registration Number: NCT00097760

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Phase 4

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: rituximab

First Posted Date: 2004-08-24

Last Posted Date: 2009-10-20

Lead Sponsor: Biogen

Target Recruit Count: 168

Registration Number: NCT00090038

Locations: 🇺🇸
USC KECK School of Medicine, Los Angeles, California, United States
🇺🇸
Tufts - New England Medical Center, Boston, Massachusetts, United States
🇺🇸
Our Lady of Mercy Medical Center, Bronx, New York, United States

and more 5 locations

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: natalizumab
Drug: placebo

First Posted Date: 2004-06-03

Last Posted Date: 2016-07-18

Lead Sponsor: Biogen

Target Recruit Count: 299

Registration Number: NCT00083759

Locations: 🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
Justus Fiechtner, MD, PC, Lansing, Michigan, United States
🇨🇦
The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada

and more 9 locations

Home Terms & Conditions Privacy Policy